Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertension
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Fimasartan (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Acronyms K-MetS
- Sponsors Boryung
- 10 Nov 2016 Status changed from recruiting to completed, according to the Korean Clinical Trials Register record.
- 29 Sep 2016 Results (n=777) assessing short-term changes of metabolic syndrome and blood pressure in hypertensive women, presented at the 26th Scientific Meeting of the International Society of Hypertension
- 29 Sep 2016 Efficacy and safety 1-year follow-up results (n=2363) of elderly patients were presented at the 26th Scientific Meeting of the International Society of Hypertension.